Valeant was once considered a runaway success story, and one that upended the pharmaceutical sector. A series of crises engulfed the company in recent months, slashing nearly two thirds off its market valuation and forcing the company to tear up its forecasts for 2016. Correspondent David Crow explains. Read the full story at "Brand New Record!" by Steve Combs

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on News in Focus when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast